Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia

diarrhea and fatigue, but these are either mild or non-existent in doses that are known to induce tumor regression.

In Phase I/II trials, perifosine has induced tumor regressions and/or caused disease stabilization in a variety of tumor types. Perifosine has shown single agent partial responses or long term disease stabilizations in solid tumors including, renal, hepatocellular, sarcoma and prostate cancer. There is also evidence of activity in hematological malignancies, especially multiple myeloma. Responding patients, including those with stable disease, have been treated for months to more than three years.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide oral gelcap), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, inorganic, iron-based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end- stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401, a novel, first-in- class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisit
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
2. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:6/19/2013)... -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ... of Medicine ( NEJM ) published results of ... tyrosine kinase (BTK) inhibitor ibrutinib in patients with relapsed/refractory ... may be effective and generally well-tolerated in patients with ... study examining the safety and efficacy of ibrutinib monotherapy ...
(Date:6/19/2013)... 19, 2013  Haemonetics Corporation (NYSE: ... the pursuit of its previously announced manufacturing transformation.  ... , Haemonetics has selected Sanmina Corporation ... production of medical devices currently manufactured in ... global provider of integrated manufacturing solutions, components, products ...
(Date:6/19/2013)... 19, 2013 /PRNewswire-iReach/ -- Robert M. Bernstein, ... transplant procedures and founder of Bernstein Medical – ... ,Best Doctors, issue of New York Magazine for ... http://photos.prnewswire.com/prnh/20130619/CG34629 ) Dr. Bernstein earned ... his reputation as world-renowned hair restoration physician, through ...
Breaking Medicine Technology:Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 2Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 3Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 4Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 5Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 6Haemonetics Announces Next Steps in Manufacturing Transformation 2Haemonetics Announces Next Steps in Manufacturing Transformation 3Haemonetics Announces Next Steps in Manufacturing Transformation 4Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 2Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 3
... Instrument announced the award of two contracts from the ... Evaluation and Research (CDER).  The first award is a ... Warehouse, and the second award supports the expansion of ... Mortara has a long-standing relationship with ...
... Sept. 30 HHS, Agency for Healthcare Research and ... grants and contracts to support projects that will help ... evidence of effectiveness. The funding announced today covers all ... HHS Secretary by AHRQ.   The projects ...
Cached Medicine Technology:Mortara Instrument Announces ECG Warehouse Contract Awards With US FDA 2HHS Awards $473 Million in Patient-Centered Outcomes Research Funding 2
(Date:6/19/2013)... 19, 2013 The benefits, NASS ... sauna but the overall experience for the majority of ... health-wise. , Mr Mouw, whose Virgina-based company enjoys an ... statement by saying that the type of sauna is ... number of counterfeit imitations which frankly, can be extremely ...
(Date:6/19/2013)... 2013 Across the globe billions of ... access to the medical advances that benefit developed western ... health care and the necessary aid to help curb ... , Outlook with Ben Kingsley is partnering ... in which these people live and highlight the invaluable ...
(Date:6/19/2013)... Denver, Colorado (PRWEB) June 19, 2013 Daily ... vertical jump training method will be published on ... a preview of the article to inform readers about the ... the declaration made by reporters working at Daily Gossip, the ... Manual Guide . , Hiller has understood during the ...
(Date:6/19/2013)... Are you using Twitter in your marketing campaigns? ... , Social media marketing is a proven and affordable ... Included in your social media campaigns should be Twitter messaging, ... and revenue for your business. , According to Statistic ... Many of these individuals are not just using the service ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Researchers from ... demonstrated several new studies at ENDO 2013, ... from June 15-18 in San Francisco.     , Mount Sinai ... as the role of prostastic acid phosphatase (PAP) in ... can stimulate the thyroid gland; revealed the prevalence of ...
Breaking Medicine News(10 mins):Health News:Health Benefits of Saunas Only Viable with Properly Constructed Models, Warns Manufacturer 2Health News:The Jump Manual Review: Reveals Hiller’s Method of Vertical Jump Training 2Health News:If Your Massage Practice Isn’t Tweeting, It Isn’t Generating New Sales: 3 Ways Twitter Helps Grow Massage Practices from Appointment-Plus 2Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 2Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 3Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 4Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 5Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 6Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 7
... Scientists know little about how the brain creates and ... obstacle in the effort to develop treatments for emotional ... is in its infancy," says Howard Hughes Medical Institute ... continue to take an enormous toll on human society." ...
... heart risk, leaked documents suggest , SATURDAY, Feb. 20 ... Avandia raises users, odds for heart attack and heart ... to confidential government reports. , The New York ... U.S. Food and Drug Administration that find that if ...
... ... it,s new shop in Beverly Hills, featuring old style barbering, straight razor shaves, in a ... ... today the official opening of its Beverly Hills store located at 9635 Brighton Way, Beverly ...
... ... chief loss mitigator for IndyMac Banks HELOC division, conducted a short sale continuing ... Honish is the first bank employee approved by any state to conduct a ... only course on the subject of short sales taught from this perspective. The ...
... ... ... , ... , ...
... ... ... ... , ...
Cached Medicine News:Health News:David Anderson to discuss what model organisms can teach us about emotion 2Health News:Remove Diabetes Drug Avandia From Market: FDA Reports 2Health News:Remove Diabetes Drug Avandia From Market: FDA Reports 3Health News:Remove Diabetes Drug Avandia From Market: FDA Reports 4Health News:The Classic Shave Company Announces the Opening of Beverly Hills Shop 2Health News:Former Bank Negotiator Turns On Bank and is Approved by the Department of Real Estate 2Health News:Former Bank Negotiator Turns On Bank and is Approved by the Department of Real Estate 3Health News:California Dental Association Foundation Expands Care to State's Underserved Communities 2Health News:California Dental Association Foundation Expands Care to State's Underserved Communities 3Health News:California Dental Association Foundation Expands Care to State's Underserved Communities 4Health News:California Dental Association Foundation Expands Care to State's Underserved Communities 5Health News:WebMD to Present at the Goldman Sachs Technology and Internet Conference 2010 2Health News:WebMD to Present at the Goldman Sachs Technology and Internet Conference 2010 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: